A research paper has been published in Oncotarget titled, “INT-1B3, an LNP formulated miR-193a-3p mimic, promotes anti-tumor immunity by enhancing T cell mediated immune responses via modulation of the tumor microenvironment and induction of immunogeni…
Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues. However, the immunosuppressive nature of the tumor microe…
Research carried out by a group from Cima and the Clínica Universidad de Navarra has described the composition of the immune system in blood samples from patients with multiple myeloma, by generating a new immunological atlas, and has revealed how chan…
Since the first immunotherapy drug to boost the body’s immune response against advanced lung cancer was introduced in the United States in 2015, survival rates of patients with the disease have improved significantly. That’s the conclusion of a recent …
Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient’s immune cells to target cancer cells. While successful in some types of leukemia, the approach has yet to realize its potential against pediatric solid tumors.
Axicabtagene ciloleucel, commonly known as axi-cel, is an innovative immunotherapy that uses modified T cells to target and destroy cancer cells. Approved for patients who have not responded to at least two prior lines of therapy, axicabtagene ciloleuc…
More than half of us are carriers of chronic herpesvirus infections.
A new form of immunotherapy using innovative nanoparticles can delay resistance to hormone therapy and help men with prostate cancer live longer.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called synovial sarcoma.
One of the most innovative treatments for pediatric cancer today is a novel form of targeted immunotherapy that was recently developed and is now increasingly being applied to pediatric cancer treatment: chimeric antigen receptors (CAR) T cell therapy….
